Cancer BiologybioRxivPreprint
Daraxonrasib (RMC-6236) is an effective targeted therapy for RAS-mutant neuroblastoma
Ronald D. Hill, Krista M. Dalton, Richard Kurupi…·Anthony C. Faber
This study shows that Daraxonrasib (RMC-6236) effectively targets RAS-mutant neuroblastoma by inhibiting MAPK signaling and enhancing cell death.
DOI 10.64898/2026.02.19.706849